Search Results

There are 7713 results for: content related to: Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity

  1. You have free access to this content
    2015 ACR/ARHP Annual Meeting Abstract Supplement

    Arthritis & Rheumatology

    Volume 67, Issue S10, October 2015, Pages: 1–4046,

    Article first published online : 5 NOV 2015, DOI: 10.1002/art.39448

  2. You have free access to this content
    ACR Meeting

    Arthritis & Rheumatism

    Volume 64, Issue S10, October 2012, Pages: S1–S1216,

    Article first published online : 11 OCT 2012, DOI: 10.1002/art.37735

  3. Pharmacokinetics and concentration–effect relationship of adalimumab in rheumatoid arthritis

    British Journal of Clinical Pharmacology

    Volume 79, Issue 2, February 2015, Pages: 286–297, David Ternant, Emilie Ducourau, Piéra Fuzibet, Céline Vignault, Hervé Watier, Thierry Lequerré, Xavier Le Loët, Olivier Vittecoq, Philippe Goupille, Denis Mulleman and Gilles Paintaud

    Article first published online : 20 JAN 2015, DOI: 10.1111/bcp.12509

  4. You have full text access to this OnlineOpen article
    Clinical Utility of Random Anti–Tumor Necrosis Factor Drug–Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis

    Arthritis & Rheumatology

    Volume 67, Issue 8, August 2015, Pages: 2011–2019, Meghna Jani, Hector Chinoy, Richard B. Warren, Christopher E. M. Griffiths, Darren Plant, Bo Fu, Ann W. Morgan, Anthony G. Wilson, John D. Isaacs, KimmeL. Hyrich, Anne Barton and on behalf of the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Collaborators

    Article first published online : 28 JUL 2015, DOI: 10.1002/art.39169

  5. You have free access to this content
    Down-titration and discontinuation strategies of tumor necrosis factor–blocking agents for rheumatoid arthritis in patients with low disease activity

    Intervention Review

    The Cochrane Library

    Noortje van Herwaarden, Alfons A den Broeder, Wilco Jacobs, Aatke van der Maas, Johannes WJ Bijlsma, Ronald F van Vollenhoven and Bart(holomeus) JF van den Bemt

    Published Online : 29 SEP 2014, DOI: 10.1002/14651858.CD010455.pub2

  6. The 12-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: Real-life data from a local registry

    Arthritis Care & Research

    Accepted manuscript online: 10 NOV 2015, Ennio Giulio Favalli, Francesca Pregnolato, Martina Biggioggero, Andrea Becciolini, Alessandra Emiliana Penatti, Antonio Marchesoni and Pier Luigi Meroni

    DOI: 10.1002/acr.22788

  7. Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab

    Journal of the European Academy of Dermatology and Venereology

    Volume 29, Issue 8, August 2015, Pages: 1576–1581, R. Bissonnette, C. Maari, K. Barber, C.W. Lynde and R. Vender

    Article first published online : 20 JAN 2015, DOI: 10.1111/jdv.12943

  8. You have full text access to this OnlineOpen article
    Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study

    Arthritis & Rheumatism

    Volume 65, Issue 1, January 2013, Pages: 28–38, Michael E. Weinblatt, Michael Schiff, Robert Valente, Désirée van der Heijde, Gustavo Citera, Cathy Zhao, Michael Maldonado and Roy Fleischmann

    Article first published online : 27 DEC 2012, DOI: 10.1002/art.37711

  9. You have full text access to this OnlineOpen article
    A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis

    International Journal of Rheumatic Diseases

    Rajendrakumar H. Jani, Rajiv Gupta, Girish Bhatia, Gaurav Rathi, Patnala Ashok Kumar, Reena Sharma, Uma Kumar, Liyakat A. Gauri, Praveen Jadhav, Girishchandra Bartakke, Vikram Haridas, Dinesh Jain and Sanjeev K. Mendiratta

    Article first published online : 14 JUL 2015, DOI: 10.1111/1756-185X.12711

  10. Adalimumab for treating rheumatoid arthritis

    Intervention Review

    The Cochrane Library

    Federico Navarro-Sarabia, Rafael Ariza-Ariza, Blanca Hernandez-Cruz and Isidro Villanueva

    Published Online : 20 JUL 2005, DOI: 10.1002/14651858.CD005113.pub2

  11. You have free access to this content
    Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis

    The Journal of Dermatology

    Volume 40, Issue 1, January 2013, Pages: 39–42, Hidetoshi Takahashi, Hitomi Tsuji, Akemi Ishida-Yamamoto and Hajime Iizuka

    Article first published online : 5 OCT 2012, DOI: 10.1111/j.1346-8138.2012.01679.x

  12. Detection of Adalimumab and Anti-Adalimumab Levels by ELISA: Clinical Considerations

    Drug Development Research

    Volume 75, Issue S1, November 2014, Pages: S11–S14, Barbara Marinari, Elisabetta Botti, Mauro Bavetta, Giulia Spallone, Arianna Zangrilli, Marina Talamonti, Antonio Richetta, Sergio Chimenti and Antonio Costanzo

    Article first published online : 8 NOV 2014, DOI: 10.1002/ddr.21186

  13. Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients

    Journal of the European Academy of Dermatology and Venereology

    Volume 27, Issue 5, May 2013, Pages: 593–600, P.P.M. van Lümig, P.C.M. van de Kerkhof, J.B.M. Boezeman, R.J.B. Driessen and E.M.G.J. de Jong

    Article first published online : 15 MAR 2012, DOI: 10.1111/j.1468-3083.2012.04496.x

  14. TNF-alpha inhibitors for ankylosing spondylitis

    Intervention Review

    The Cochrane Library

    Lara J Maxwell, Jane Zochling, Annelies Boonen, Jasvinder A Singh, Mirella MS Veras, Elizabeth Tanjong Ghogomu, Maria Benkhalti Jandu, Peter Tugwell and George A Wells

    Published Online : 18 APR 2015, DOI: 10.1002/14651858.CD005468.pub2

  15. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study

    British Journal of Dermatology

    Volume 167, Issue 3, September 2012, Pages: 658–667, C. Leonardi, J.M. Sobell, J.J. Crowley, U. Mrowietz, Y. Bao, P.M. Mulani, Y. Gu and M.M. Okun

    Article first published online : 20 AUG 2012, DOI: 10.1111/j.1365-2133.2012.11041.x

  16. You have free access to this content
    Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial

    Arthritis & Rheumatism

    Volume 56, Issue 2, February 2007, Pages: 476–488, Dafna D. Gladman, Philip J. Mease, Christopher T. Ritchlin, Ernest H. S. Choy, John T. Sharp, Peter A. Ory, Renee J. Perdok and Eric H. Sasso

    Article first published online : 30 JAN 2007, DOI: 10.1002/art.22379

  17. Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease

    Alimentary Pharmacology & Therapeutics

    Volume 40, Issue 9, November 2014, Pages: 1044–1055, C. Ma, V. Huang, D. K. Fedorak, K. I. Kroeker, L. A. Dieleman, B. P. Halloran and R. N. Fedorak

    Article first published online : 3 SEP 2014, DOI: 10.1111/apt.12940

  18. Caspase activation and apoptosis induction by adalimumab: Demonstration in vitro and in vivo in a chimeric mouse model

    Inflammatory Bowel Diseases

    Volume 12, Issue 1, January 2006, Pages: 22–28, Chong Shen, Gert Van Assche, Paul Rutgeerts and Jan L Ceuppens

    Article first published online : 14 DEC 2006, DOI: 10.1097/01.MIB.0000194185.69800.07

  19. Risk–benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease

    Inflammatory Bowel Diseases

    Volume 17, Issue 1, January 2011, Pages: 127–140, Edward V. Loftus Jr, Scott J. Johnson, Si-Tien Wang, Eric Wu, Parvez M. Mulani and Jingdong Chao

    Article first published online : 1 JUN 2010, DOI: 10.1002/ibd.21341

  20. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: Results from the CHARM trial

    Inflammatory Bowel Diseases

    Volume 18, Issue 5, May 2012, Pages: 818–825, David T. Rubin, Parvez Mulani, Jingdong Chao, Paul F. Pollack, Arielle G. Bensimon, Andrew P. Yu and Subrata Ghosh

    Article first published online : 1 SEP 2011, DOI: 10.1002/ibd.21836